Michigan’s Marijuana Tax Experiment Should Be An Urgent Warning To Other States (Op-Ed)
#35
Clinical Context
Background information relevant to the evolving cannabis medicine landscape.
Michigan’s experience with its 10% state cannabis tax, layered atop federal excise taxes and local levies, has created a cumulative tax burden exceeding 40% in some jurisdictions, pricing legal products out of reach for many patients and driving continued reliance on illicit markets. This tax structure has demonstrably reduced legal cannabis sales and tax revenue while failing to achieve public health or regulatory objectives, instead creating perverse incentives that undermine the legitimate medical cannabis market. For clinicians prescribing cannabis therapeutically, high tax burdens directly impact patient adherence and access to regulated, quality-controlled products, potentially forcing patients toward unregulated alternatives with unknown potency and contaminants. Other states considering or implementing cannabis taxation should learn from Michigan’s mistakes by designing more modest and strategically structured tax systems that maintain the price competitiveness necessary to transition patients away from illicit sources. Clinicians should be aware that tax policy significantly influences their patients’ ability to obtain legal medical cannabis, and advocacy for reasonable taxation structures is relevant to optimal patient outcomes and public health goals.
“We’re seeing in Michigan what happens when tax policy outpaces clinical infrastructure: patients and providers are caught between a legal market that’s prohibitively expensive and an informal market that offers no quality control, and that’s a public health failure regardless of your views on legalization.”
? While Michigan’s experience with cannabis tax revenue allocation offers important fiscal lessons for other states considering legalization, healthcare providers should recognize that tax policy and regulatory frameworks operate independently from clinical evidence about cannabis safety and efficacy. The article’s focus on state budgeting and tax competition does not address the clinical questions that ultimately matter in practice: the neurobiological effects of various cannabinoid formulations, optimal dosing for specific conditions, and long-term health outcomes in diverse patient populations. Clinicians must remain cautious about assuming that successful tax implementation or market expansion reflects a well-characterized therapeutic product, as state regulatory decisions are often driven by revenue generation and commercial interests rather than robust clinical data. The complexity here is that patients may have increased access to cannabis products regardless of tax structures, making it essential for providers to stay informed about emerging clinical evidence, screen for problematic use patterns, and maintain awareness of how their own jurisdiction’s tax and regulatory environment may influence patient purchasing behavior
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it:
